Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1237635 | 0.90 | FUCA1 (0.45) | FUCA1S1PR5S1PR1THRBACHE | |
| SCHEMBL1237636 | 0.90 | FUCA1 (0.45) | FUCA1S1PR5S1PR1THRBACHE | |
| SCHEMBL6765544 | 0.90 | FUCA1 (0.45) | FUCA1S1PR5S1PR1THRBACHE | |
| SCHEMBL3880527 | 0.84 | FUCA1 (0.54) | FUCA1S1PR5S1PR1THRBCYP1A2 | |
| SCHEMBL3884231 | 0.84 | FUCA1 (0.54) | FUCA1S1PR5S1PR1THRBCYP1A2 | |
| SCHEMBL25217562 | 0.80 | FUCA1 (0.38) | DPP4FUCA1THRBACHESIGMAR1 | |
| SCHEMBL16764987 | 0.80 | FUCA1 (0.38) | DPP4FUCA1THRBACHESIGMAR1 | |
| SCHEMBL25595509 | 0.80 | FUCA1 (0.38) | DPP4FUCA1THRBACHESIGMAR1 | |
| SCHEMBL6214178 | 0.79 | DPP4 (0.48) | DPP4FUCA1S1PR5S1PR1ACHE | |
| SCHEMBL6214181 | 0.79 | DPP4 (0.48) | DPP4FUCA1S1PR5S1PR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| EP-2010488-A2 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007117559-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | DPP4 34/4885FUCA1 254/4885S1PR5 3614/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | DPP4 39/4885FUCA1 303/4885S1PR5 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.